Eli Lilly LLY shares are trading higher on Wednesday. The strength is potentially in sympathy with Biogen BIIB which gained following a favorable FDA briefing document for its Alzheimer's drug. Lilly's solanezumab had previously failed Alzheimer's trials.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Eli Lilly shares were trading up 13.93% at $149.32 on Wednesday. The stock has a 52-week high of $170.75 and a 52-week low of $110.51.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.